NEW YORK (GenomeWeb) – Interleukin Genetics said Monday that it plans to liquidate its assets three weeks after it announced it was laying off 63 percent of its workforce and suspending sales of its controversial genetic test for severe gum disease and elevated systemic inflammation.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.
This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.
This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.